Last reviewed · How we verify
CEFOTIAM
Cefotiam is a marketed antibiotic that binds to the vasoactive intestinal polypeptide receptor 1, positioning it in a niche segment of the antibiotic market. Its key strength lies in its unique mechanism of action, which differentiates it from other cephalosporins such as cefoxitin, cefuroxime, cefaclor, cefotetan, and cefonicid, all of which are off-patent and widely available as generics. The primary risk is the expiration of its key composition patent in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | CEFOTIAM |
|---|---|
| Drug class | cefotiam |
| Target | Vasoactive intestinal polypeptide receptor 1, Matrix metalloproteinase-9, Bacterial penicillin-binding protein |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 1988 |
Approved indications
Common side effects
Key clinical trials
- Prophylactic Use of Antibiotics in Endoscopic Injection of Tissue Adhesive in Gastric Varices (NA)
- Efficiency and Safety of Prophylactic Use of Antibiotics in Endoscopic Injection of Tissue Adhesive in Gastric Varices (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CEFOTIAM CI brief — competitive landscape report
- CEFOTIAM updates RSS · CI watch RSS